



What is claimed is:

1. A compound having Formula I:



and pharmaceutically acceptable salts thereof, where:

- X¹ and X² are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, -(CH₂)_m-halogen, -(CH₂)_m-heteroaryl, -(CH₂)_m-SOR³, -(CH₂)_m-OCOR³, -(CH₂)_m-OSO₂R³, -(CH₂)_m-OSO₂NR⁴R⁵, -(CH₂)_m-NR⁶COR³, -10 (CH₂)_m-NR⁶SO₂R³, -(CH₂)_m-NR³SO₂NR⁴R⁵, -(CH₂)_mNR⁴R⁵, -(CH₂)_mOR³, -CN, -NO₂, -CF_(3-n)H_n, -(CH₂)_m-O(CH₂)_mR³, -(CH₂)_m-O(CH₂)_m-OR³, -(CH₂)_m-O(CH₂)_m-NR⁴R⁵, -(CH₂)_mR³, -(CH₂)_mCO₂R³, -(CH₂)_mCOR³, -(CH₂)_mCONR⁴R⁵, -(CH₂)_mNR⁶COR³, -(CH₂)_mNR⁶CONR⁴R⁵, -(CH₂)_mSO₂R³, -(CH₂)_mSO₂NR⁴R⁵,



together to form a substituted or unsubstituted three to eight member ring wherein 0 to 3 atoms of the ring are heteroatoms;

A is aryl, arylcycloalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkenyl;

- 20 M is arylene, heteroarylene, cycloalkylene, heterocycloalkylene, cycloalkenylene or heterocycloalkenylene;

Q is -CONR⁴R⁵, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl;


R¹ is hydrogen, alkyl, aryl, heteroaryl or alkenyl;

- 25 R² is hydrogen, alkyl, aryl, heteroaryl, alkenyl, cycloalkyl, cycloalkylalkyl, aralkyl, heteroaralkyl, heterocycloalkylalkyl, carboxy, -(CH₂)_mNR⁴R⁵, -(CH₂)_mOR³, -(CH₂)_mSR³, -(CH₂)_mCONR⁴R⁵, or -(CH₂)_mNR⁶COR³;

R³ is hydrogen, alkyl, aryl, heteroaryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aralkyl, or heteroarylalkyl;

R⁶ is hydrogen, alkyl, aryl, heteroaryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aralkyl, or heteroarylalkyl;

5 R⁴ and R⁵ are each independently hydrogen, alkyl, aryl, heteroaryl, alkenyl,



m is 0 to 8;

10 n is 0 to 2; and


p is 1 to 3;

with the proviso that when R¹ and R² are H, neither X¹ nor X² is H.

2. The compound of claim 1, wherein A is aryl or heteroaryl.


15

3. The compound of claim 2, wherein A is



20 wherein Y is CH or N; and R⁸ is hydrogen, halo, or C₁-C₆ alkyl.

4. The compound of claim 3, wherein A is




5. The compound of claim 4, wherein A is 4-chlorophenyl or 5-chloro-2-pyridyl.

10

6. The compound of claim 1, wherein M is arylene or heteroarylene.


7. The compound of claim 6, wherein M is



15

20

8. The compound of claim 7, wherein M is




wherein R⁹ is hydrogen, methyl, trifluoromethyl, Cl, Br, or F.

9. The compound of claim 8, wherein M is phenylene-1,4-diyl, 2-fluoro-
10 phenylene-1,4-diyl, 2-methyl-phenylene-1,4-diyl, 2-trifluoromethyl-phenylene-
1,4-diyl, or pyridine-2,5-diyl.

10. The compound of claim 1, wherein Q is aryl, heteroaryl or
heterocycloalkyl.

15

11. The compound of claim 10, wherein Q is




5 $\text{N}=\text{C}-\overset{\text{O}}{\parallel}\text{-C}_1\text{-C}_6\text{alkyl}$, $\text{N}=\text{C}-\overset{\text{O}}{\parallel}\text{-O-C}_1\text{-C}_6\text{alkyl}$, $-\overset{\text{O}}{\parallel}\text{-C-O-}$ aralkyl, $\text{N}=\text{C}-\overset{\text{O}}{\parallel}\text{-S-C}_1\text{-C}_6\text{alkyl}$,

or $\text{N}=\overset{\text{O}}{\text{C}}-\overset{\text{H}}{\text{N}}-\text{C}_1\text{-C}_6\text{alkyl}$; R¹⁴ is hydrogen, halo, C₁-C₆ alkyl, -SO₂NR¹²R¹³, -SO₂alkyl or oxo; R¹⁶ and R¹⁷ are independently hydrogen, C₁-C₆ alkyl, or are joined together to form a saturated or unsaturated 3 to 8 membered ring; and R¹⁰ is hydrogen, halo, C₁-C₆ alkyl, -SO₂NR¹²R¹³, or -SO₂alkyl, C₁-C₆ alkyl,

10 wherein R¹² and R¹³ are independently hydrogen, C₁-C₆ alkyl, or are joined together to form a saturated 5 to 7 membered ring.

12. The compound of claim 11, wherein Q is




13. The compound of claim 11, wherein Q is 2-methanesulfonylphenyl, 2-sulfamoylphenyl, 2-oxo-2H-pyridin-1-yl, or 2-oxo-piperidin-1-yl.
- 10 14. The compound of claim 1, wherein X¹ and X² are hydrogen, alkyl, -(CH₂)_mOR³, or alkenyl.
15. The compound of claim 1, wherein X¹ and X² are alkyl, -(CH₂)_mOR³, alkenyl or -CH₂-NR⁷R⁷ where R⁷ and R⁷ are independently hydrogen, -C₁-C₆
- 15 alkyl $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{C}_1\text{-}\text{C}_6\text{alkyl, } -\text{C}-\text{O}-\text{C}_1\text{-}\text{C}_6\text{alkyl, } \\ -\text{C}-\text{O-} \end{array}$ aralkyl, $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{S}-\text{C}_1\text{-}\text{C}_6\text{alkyl, or } -\text{C}-\text{N}-\text{C}_1\text{-}\text{C}_6\text{alkyl} \\ \text{H} \end{array}$. .
16. The compound of claim 1, wherein X¹ and X² are hydrogen, methyl, -CH₂-OH, -CH₂-NH₂, -CH₂-N(CH₃)₂, or -CH₂-N(CH₂CH₃)₂.

17. The compound of claim 1, wherein X¹ and X² together form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclopentenyl ring.
- 5 18. The compound of claim 1, wherein X¹ and X² together are
-
- wherein R¹⁵ and R^{15'} are independently hydrogen, -(CH₂)₁₋₆-OH, -(CH₂)₁₋₆-O-C₁-C₆ alkyl, -(CH₂)₁₋₆-NH₂, -COOH, or -OH; and E is O, S, or NR¹⁶ wherein R¹⁶ is
- 10 hydrogen, -C₁-C₆ alkyl, $\text{--}\overset{\text{O}}{\underset{\parallel}{\text{C}}}\text{--C}_1\text{--C}_6\text{alkyl}$, $\text{--}\overset{\text{O}}{\underset{\parallel}{\text{C}}}\text{--O--C}_1\text{--C}_6\text{alkyl}$,
- hydrogen, -C₁-C₆ alkyl, $\text{--}\overset{\text{O}}{\underset{\parallel}{\text{C}}}\text{--O--aralkyl}$, $\text{--}\overset{\text{O}}{\underset{\parallel}{\text{C}}}\text{--S--C}_1\text{--C}_6\text{alkyl}$, or $\text{--}\overset{\text{O}}{\underset{\parallel}{\text{C}}}\text{--N--C}_1\text{--C}_6\text{alkyl}$.
19. The compound of claim 1, wherein R² is alkyl, aryl, heteroaryl, cycloalkyl,
- 15 cycloalkylalkyl, aralkyl, heteroaralkyl, heterocycloalkylalkyl, carboxy, -(CH₂)_mNR⁴R⁵, -(CH₂)_mOR³, -(CH₂)_mSR³, -(CH₂)_mCONR⁴R⁵, or -(CH₂)_mNR⁶COR³; wherein R³, R⁴, R⁵ and R⁶ as described in claim 1.
20. The compound of claim 19, wherein R² is C₁-C₆ alkyl, phenyl, pyridyl,
- 20 cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclopentylethyl, benzyl, 2-pyridinylmethyl, 3-pyridinylmethyl, 4-pyridinylmethyl, 3-(2-pyridinyl)-propyl, thienylmethyl, 2-morpholin-4-yl-ethyl, 2-thiomorpholin-4-yl-ethyl, -(CH₂)₁₋₃NH₂,



$-(CH_2)_{1-3}N(C_1-C_6\text{alkyl})_2$, $-(CH_2)_{1-3}NHC_1-C_6\text{alkyl}$, $-(CH_2)_{1-3}OC_1-C_6\text{alkyl}$, $-(CH_2)_{1-3}SC_1-C_6\text{alkyl}$, $-(CH_2)_{1-3}\text{CONH}_2$, $-(CH_2)_{1-3}\text{CON}(C_1-C_6\text{alkyl})_2$, $-(CH_2)_{1-3}\text{CONHC}_1-C_6\text{alkyl}$, or $-(CH_2)_{1-3}\text{NHCOC}_1-C_6\text{alkyl}$.

5 21. The compound of claim 1, wherein where A is



wherein Y is CH or N; and R⁸ is hydrogen, Cl, Br, or F;

M is




or

R⁹

; wherein R⁹ is hydrogen, Cl, Br, or F;

10

Q is




wherein G is

NH , $\text{N}-(\text{C}_1\text{-C}_6\text{alkyl})$ or $\text{N}-\overset{\text{O}}{\parallel}\text{C}-\text{C}_1\text{-C}_6\text{alkyl}$; R^{14} is hydrogen, $-\text{SO}_2\text{NR}^{12}\text{R}^{13}$, -

$-\text{SO}_2\text{alkyl}$ or oxo; and R^{10} is hydrogen, Cl, Br, F, $-\text{SO}_2\text{NR}^{12}\text{R}^{13}$, or $-\text{SO}_2\text{alkyl}$,


- 5 where R^{12} and R^{13} are independently hydrogen, or $\text{C}_1\text{-C}_6$ alkyl;

X_1 and X_2 are hydrogen, methyl, $-\text{CH}_2\text{-OH}$, $-\text{CH}_2\text{-NR}^7\text{R}^{7'}$ where R^7 and $\text{R}^{7'}$ are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl, or X_1 and X_2 together form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclopentenyl ring or together are



wherein R^{15} and $\text{R}^{15'}$ are independently hydrogen, $-(\text{CH}_2)_{1-6}\text{-OH}$, $-(\text{CH}_2)_{1-6}\text{-O-C}_1\text{-C}_6\text{alkyl}$, $-(\text{CH}_2)_{1-6}\text{-NH}_2$, $-\text{COOH}$, or $-\text{OH}$; and E is O, S, or NR^{16} where R^{16} is R^{16}

is hydrogen, C₁-C₆ alkyl, $\text{--C}(=\text{O})\text{--C}_1\text{--C}_6\text{alkyl}$, $\text{--C}(=\text{O})\text{--O--C}_1\text{--C}_6\text{alkyl}$, or



- R¹ and R³ are each independently hydrogen, or C₁-C₆alkyl; and
R² is hydrogen, C₁-C₆ alkyl, phenyl, pyridyl, cyclopropyl, cyclopropylmethyl,
5 cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-
cyclopentylethyl, benzyl, 2-pyridinylmethyl, 3-pyridinylmethyl, 4-
pyridinylmethyl, 3-(2-pyridinyl)-propyl, thienylmethyl, 2-morpholin-4-yl-ethyl, 2-
thiomorpholin-4-yl-ethyl, -(CH₂)₁₋₃NH₂, -(CH₂)₁₋₃N(C₁-C₆alkyl)₂, -(CH₂)₁₋₃NHC₁-
C₆alkyl, -(CH₂)₁₋₃OC₁-C₆alkyl, -(CH₂)₁₋₃SC₁-C₆alkyl, -(CH₂)₁₋₃CONH₂, -(CH₂)₁₋₃
10 CON(C₁-C₆alkyl)₂, -(CH₂)₁₋₃CONHC₁-C₆alkyl, or -(CH₂)₁₋₃NHCOC₁-C₆alkyl.

22. The compound of claim 1, wherein the compounds is
1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (3-fluoro-2'-
methanesulfonyl-biphenyl-4-yl)-amide;
15 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid (3-fluoro-2'-
sulfamoyl-biphenyl-4-yl)-amide;
2-[3-(5-Chloro-pyridin-2-yl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-
yl)-2-methyl-propionamide;
20 2-[3-(4-Chloro-phenyl)-ureido]-N-(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-2-
methyl-propionamide;
4-[3-(4-Chloro-phenyl)-ureido]-tetrahydro-thiopyran-4-carboxylic acid (3-fluoro-
2'-sulfamoyl-biphenyl-4-yl)-amide;
1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (3-fluoro-2'-
sulfamoyl-biphenyl-4-yl)-amide;
25 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid (3-fluoro-2'-
methanesulfonyl-biphenyl-4-yl)-amide;
4-[3-(4-Chloro-phenyl)-ureido]-tetrahydro-pyran-4-carboxylic acid (3-fluoro-2'-
sulfamoyl-biphenyl-4-yl)-amide;
1-[3-(4-Chloro-phenyl)-ureido]-cyclopentanecarboxylic acid (2'-methanesulfonyl-
30 biphenyl-4-yl)-amide;

- 1-[3-(4-Chloro-phenyl)-ureido]-cyclohexanecarboxylic acid (2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 2-[3-(4-Chloro-phenyl)-1-methyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 5 2-[3-(4-Chloro-phenyl)-1,3-dimethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-ureido]-3-hydroxy-2-hydroxymethyl-N-(2'-sulfamoyl-biphenyl-4-yl)-propionamide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 10 2-[3-(4-Chloro-phenyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-2-methyl-propionamide;
- 2-[3-(4-Chloro-phenyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 15 1-[3-(4-Chloro-phenyl)-ureido]-cyclopent-3-enecarboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide; and
- 2-[3-(4-Chloro-phenyl)-3-methyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- (1S,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-
- 20 cyclopropanecarboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- (1R,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-
- cyclopropanecarboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 25 (1R, 2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-
- cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- (1S, 2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-
- cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-
- 30 amide;
- 2-[3-(4-Chloro-phenyl)-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-2-methyl-propionamide;

- 2-[3-(5-Chloro-pyridin-2-yl)-ureido]-2-methyl-N-[4-(2-oxo-piperidin-1-yl)-phenyl]-propionamide;
- 2-[3-(4-Chloro-phenyl)-ureido]-2-methyl-N-[4-(2-oxo-piperidin-1-yl)-phenyl]-propionamide;
- 5 2-[3-(5-Chloro-pyridin-2-yl)-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-2-methyl-propion amide;
- N-[2-Fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-2-[3-(4-fluoro-phenyl)-ureido]-2-methyl-propionamide;
- 10 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid [4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid [4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 15 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 1-[3-(4-Fluoro-phenyl)-ureido]-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclohexanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 20 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclohexanecarboxylic acid [4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclohexanecarboxylic acid [4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 25 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclohexanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 1-[3-(4-Fluoro-phenyl)-ureido]-cyclohexanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 2-[3-(4-Chloro-phenyl)-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-3-hydroxy-2-hydroxymethyl-propionamide;
- 30 2-[3-(5-Chloro-pyridin-2-yl)-ureido]-3-hydroxy-2-hydroxymethyl-N-[4-(2-oxo-piperidin-1-yl)-phenyl]-propionamide;

- 2-[3-(4-Chloro-phenyl)-ureido]-3-hydroxy-2-hydroxymethyl-N-[4-(2-oxo-piperidin-1-yl)-phenyl]-propionamide;
- 2-[3-(5-Chloro-pyridin-2-yl)-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-3-hydroxy-2-hydroxymethyl-propionamide;
- 5 N-[2-Fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-2-[3-(4-fluoro-phenyl)-ureido]-3-hydroxy-2-hydroxymethyl-propionamide;
- 2-[3-(4-Chloro-phenyl)-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-acetamide;
- 10 2-[3-(5-Chloro-pyridin-2-yl)-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-acetamide;
- 2-[3-(5-Chloro-pyridin-2-yl)-ureido]-N-[4-(2-oxo-piperidin-1-yl)-phenyl]-acetamide;
- 15 2-[3-(4-Chloro-phenyl)-ureido]-N-[4-(2-oxo-piperidin-1-yl)-phenyl]-acetamide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid [5-(2-methanesulfonyl-phenyl)-pyridin-2-yl]-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid [5-(2-sulfamoyl-phenyl)-pyridin-2-yl]-amide;
- 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid [5-(2-methanesulfonyl-phenyl)-pyridin-2-yl]-amide;
- 20 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid [5-(2-sulfamoyl-phenyl)-pyridin-2-yl]-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (2'-methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (2'-sulfamoyl-3-trifluoromethyl-biphenyl-4-yl)-amide;
- 25 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid (2'-methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide;
- 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid (2'-methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide;
- 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid (2'-sulfamoyl-3-trifluoromethyl-biphenyl-4-yl)-amide;
- 30 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (2'-methanesulfonyl-3-methyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (3-methyl-2'-sulfamoyl-biphenyl-4-yl)-amide;

- 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid (2'-methanesulfonyl-3-methyl-biphenyl-4-yl)-amide;
- 1-[3-(5-Chloro-pyridin-2-yl)-ureido]-cyclopropanecarboxylic acid (3-methyl-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 5 2-[3-(5-Chloro-pyridin-2-yl)-1-methyl-ureido]-N-(2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-methyl-ureido]-N-(2'-sulfamoyl-biphenyl-4-yl)-acetamide;
- 2-[3-(5-Chloro-pyridin-2-yl)-1-methyl-ureido]-N-(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-acetamide;
- 10 2-[3-(4-Chloro-phenyl)-1-methyl-ureido]-N-(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-acetamide;
- 2-[3-(5-Chloro-pyridin-2-yl)-1-methyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 15 2-[3-(4-Chloro-phenyl)-1-methyl-ureido]-N-(2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid (2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid (2'-sulfamoyl-biphenyl-4-yl)-amide;
- 20 1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 25 3-[3-(4-Chloro-phenyl)-ureido]-pyrrolidine-3-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 3-[3-(4-Chloro-phenyl)-ureido]-pyrrolidine-3-carboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-3-hydroxymethyl-cyclobutanecarboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 30 1-[3-(4-Chloro-phenyl)-ureido]-3-hydroxymethyl-cyclobutanecarboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;

- 1-[3-(4-Chloro-phenyl)-ureido]-2-methoxymethyl-cyclopropanecarboxylic acid
(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-2-methoxymethyl-cyclopropanecarboxylic acid
(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 5 2-Aminomethyl-1-[3-(4-chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (3-
fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 2-Aminomethyl-1-[3-(4-chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (3-
fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 10 2-[3-(4-Chloro-phenyl)-ureido]-2-(3-fluoro-2'-methanesulfonyl-biphenyl-4-
ylcarbamoyl)-cyclopropanecarboxylic acid;
- 2-[3-(4-Chloro-phenyl)-ureido]-2-(3-fluoro-2'-sulfamoyl-biphenyl-4-
ylcarbamoyl)-cyclopropanecarboxylic acid;
- 3-[3-(4-Chloro-phenyl)-ureido]-1-methyl-pyrrolidine-3-carboxylic acid (3-fluoro-
2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 15 3-[3-(4-Chloro-phenyl)-ureido]-1-methyl-pyrrolidine-3-carboxylic acid (3-fluoro-
2'-sulfamoyl-biphenyl-4-yl)-amide;
- 1-Acetyl-3-[3-(4-chloro-phenyl)-ureido]-pyrrolidine-3-carboxylic acid (3-fluoro-
2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 1-Acetyl-3-[3-(4-chloro-phenyl)-ureido]-pyrrolidine-3-carboxylic acid (3-fluoro-
20 2'-sulfamoyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-3-methoxymethyl-cyclobutanecarboxylic acid (3-
fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-3-methoxymethyl-cyclobutanecarboxylic acid (3-
fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 25 3-Aminomethyl-1-[3-(4-chloro-phenyl)-ureido]-cyclobutanecarboxylic acid (3-
fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 3-Aminomethyl-1-[3-(4-chloro-phenyl)-ureido]-cyclobutanecarboxylic acid (3-
fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 3-[3-(4-Chloro-phenyl)-ureido]-3-(3-fluoro-2'-methanesulfonyl-biphenyl-4-
30 ylcarbamoyl)-cyclobutanecarboxylic acid;
- 3-[3-(4-Chloro-phenyl)-ureido]-3-(3-fluoro-2'-sulfamoyl-biphenyl-4-
ylcarbamoyl)-cyclobutanecarboxylic acid;

- 4-[3-(4-Chloro-phenyl)-ureido]-piperidine-4-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 4-[3-(4-Chloro-phenyl)-ureido]-piperidine-4-carboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 5 4-[3-(4-Chloro-phenyl)-ureido]-1-methyl-piperidine-4-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 4-[3-(4-Chloro-phenyl)-ureido]-1-methyl-piperidine-4-carboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 1-Acetyl-4-[3-(4-chloro-phenyl)-ureido]-piperidine-4-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 10 1-Acetyl-4-[3-(4-chloro-phenyl)-ureido]-piperidine-4-carboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-3,4-dihydroxy-cyclopentanecarboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 15 1-[3-(4-Chloro-phenyl)-ureido]-3,4-dihydroxy-cyclopentanecarboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 3-[3-(4-Chloro-phenyl)-ureido]-tetrahydro-furan-3-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 3-[3-(4-Chloro-phenyl)-ureido]-tetrahydro-furan-3-carboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 20 3-[3-(4-Chloro-phenyl)-ureido]-tetrahydro-thiophene-3-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 3-[3-(4-Chloro-phenyl)-ureido]-1-methyl-pyrrolidine-3-carboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 25 1-Acetyl-3-[3-(4-chloro-phenyl)-ureido]-pyrrolidine-3-carboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;
- 1-Acetyl-3-[3-(4-chloro-phenyl)-ureido]-azetidine-3-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 1-Acetyl-3-[3-(4-chloro-phenyl)-ureido]-azetidine-3-carboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;
- 30 1-[3-(4-Chloro-phenyl)-1-methyl-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;

- 1-[3-(4-Chloro-phenyl)-1-methyl-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;

1-[3-(4-Chloro-phenyl)-1-methyl-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;

3-[3-(4-Chloro-phenyl)-ureido]-tetrahydro-thiophene-3-carboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;

3-[3-(4-Chloro-phenyl)-ureido]-1-methyl-azetidine-3-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;

3-[3-(4-Chloro-phenyl)-ureido]-1-methyl-azetidine-3-carboxylic acid (3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide;

1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;

1-[3-(4-Chloro-phenyl)-ureido]-2-methoxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-amide;

3-Amino-2-aminomethyl-2-[3-(4-chloro-phenyl)-ureido]-N-(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-propionamide;

3-Amino-2-aminomethyl-2-[3-(4-chloro-phenyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-propionamide;

2-[3-(4-Chloro-phenyl)-ureido]-3-ethylamino-2-ethylaminomethyl-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-propionamide;

2-[3-(4-Chloro-phenyl)-1-cyclopropylmethyl-ureido]-N-(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-acetamide;

2-[3-(4-Chloro-phenyl)-1-cyclopropylmethyl-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-acetamide;

2-[3-(4-Chloro-phenyl)-1-cyclopropylmethyl-ureido]-N-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-acetamide;

2-[3-(5-Chloro-pyridin-2-yl)-1-cyclopropylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;

2-[3-(4-Chloro-phenyl)-1-cyclopropyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;

2-[3-(5-Chloro-pyridin-2-yl)-1-cyclopropylmethyl-ureido]-N-(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-acetamide;

- 2-[3-(5-Chloro-pyridin-2-yl)-1-cyclopropylmethyl-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-acetamide;
- 2-[3-(5-Chloro-pyridin-2-yl)-1-cyclopropylmethyl-ureido]-N-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-acetamide;
- 5 2-[3-(4-Chloro-phenyl)-1-isopropyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-cyclopentyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-cyclopentylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 10 2-[3-(4-Chloro-phenyl)-1-phenyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-(2-cyclopropyl-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-phenyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 15 2-[3-(4-Chloro-phenyl)-1-thiophen-3-ylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-pyridin-3-ylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-cyclohexylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 20 2-[3-(4-Chloro-phenyl)-1-(2-cyclopentyl-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-thiophen-2-ylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 25 2-[3-(4-Chloro-phenyl)-1-pyridin-2-ylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-pyridin-4-ylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-(2-ethoxy-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 30 2-[3-(4-Chloro-phenyl)-1-(2-methylsulfanyl-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;


- {3-(4-Chloro-phenyl)-1-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-methyl]-ureido}-acetic acid;
- 2-[3-(4-Chloro-phenyl)-1-(2-morpholin-4-yl-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 5 2-[3-(4-Chloro-phenyl)-1-(2-thiomorpholin-4-yl-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-phenethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 10 2-[3-(4-Chloro-phenyl)-1-(2-methylsulfanyl-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-methylcarbamoylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 15 2-{3-(4-Chloro-phenyl)-1-[2-(4-methyl-piperazin-1-yl)-ethyl]-ureido}-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[1-(2-Acetylaminoo-ethyl)-3-(4-chloro-phenyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 20 2-[3-(4-Chloro-phenyl)-1-(2,2-dimethyl-propyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 3-[3-(4-Chloro-phenyl)-ureido]-3-(3-fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-1-carboxylic acid benzyl ester;
- 2-[3-(4-Chloro-phenyl)-1-(2,2-dimethyl-propyl)-ureido]-N-[2-fluoro-4-(2-oxo-piperidin-1-yl)-phenyl]-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-cyclobutylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 25 2-[3-(4-Chloro-phenyl)-1-cyclopropylmethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-(2-methoxy-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-isobutyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 30 2-[3-(4-Chloro-phenyl)-1-(2-dimethylamino-ethyl)-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;

- 2-[1-Benzyl-3-(4-chloro-phenyl)-ureido]-N-(3-fluoro-2' methanesulfonyl-biphenyl-4-yl)-acetamide;
- 2-[3-(4-Chloro-phenyl)-1-(4-methoxy-benzyl) ureido]- N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide;
- 5 (1R,2S)-(1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide;
- (1S,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide;
- 10 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid [2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid [2-fluoro-4-(5-methyl-pyrazol-1-yl)-phenyl]-amide;
- 15 (1R,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(5-methyl-pyrazol-1-yl)-phenyl]-amide;
- (1S,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(5-methyl-pyrazol-1-yl)-phenyl]-amide;
- 20 2-[3-(4-Chloro-phenyl)-1-cyclopropylmethyl-ureido]-N-[2-fluoro-4-(5-methyl-pyrazol-1-yl)-phenyl]-acetamide;
- 1-[3-(4-Chloro-phenyl)-ureido]-cyclopropanecarboxylic acid [4-(3,5-dimethyl-pyrazol-1-yl)-2-fluoro-phenyl]-amide;
- 25 2-[3-(4-Chloro-phenyl)-1-cyclopropylmethyl-ureido]-N-[4-(3,5-dimethyl-pyrazol-1-yl)-2-fluoro-phenyl]-acetamide;
- (1R,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid (2-fluoro-4-pyrazol-1-yl-phenyl)-amide;
- (1S,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid (2-fluoro-4-pyrazol-1-yl-phenyl)-amide;
- 30 (1R,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(3-methyl-pyrazol-1-yl)-phenyl]-amide;

- (1S,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(3-methyl-pyrazol-1-yl)-phenyl]-amide;
- (1R,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(2-methyl-imidazol-1-yl)-phenyl]-amide;
- 5 (1S,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(2-methyl-imidazol-1-yl)-phenyl]-amide;
- 10 (1R,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [4-(2,5-dihydro-pyrrole-1-carbonyl)-2-fluoro-phenyl]-amide;
- (1S,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [4-(2,5-dihydro-pyrrole-1-carbonyl)-2-fluoro-phenyl]-amide;
- 15 (1R,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(pyrrolidine-1-carbonyl)-phenyl]-amide;
- (1S,2S)-1-[3-(4-Chloro-phenyl)-ureido]-2-hydroxymethyl-cyclopropanecarboxylic acid [2-fluoro-4-(pyrrolidine-1-carbonyl)-phenyl]-amide;
- 20 (1R,2S)-2-(Acetylamino-methyl)-1-[3-(4-chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- (1R,2S)-2-(Acetylamino-methyl)-1-[3-(4-chloro-phenyl)-ureido]-cyclopropanecarboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide;
- 25 or a pharmaceutically acceptable salt thereof.
- 30 23. A process for the preparation of compounds of Formula I, wherein P¹ is a protecting group, Y¹ is a halogen and X¹, X², A, M, and Q are as defined above, comprising


(a) contacting an amino acid having Formula III with a reagent capable of forming a protecting group on the amino group of the amino acid to form a compound with Formula IV

5




(b) activating of the carboxylic acid of Formula IV and contacting it with an amino compound of the formula $\text{H}_2\text{N}-\text{M}-\text{Y}^1$ to form a compound of Formula V

10




(c) coupling the compound of Formula V with a compound having Q to form a compound of Formula VI

15



20


(d) removing the amino protecting group of the compound of Formula VI and contacting the resulting free amine with an isocyanate having A to form a compound of Formula I



5


24. A process for the preparation of compounds of Formula I, wherein P^1 is a protecting group, and X^1 , X^2 , A , M , and Q are as defined above, comprising

- 10 (a) contacting an amino acid having Formula X with a reagent capable of forming a protecting group on the amino group of the amino acid to form a compound with Formula XI




15

- (b) activating of the carboxylic acid of Formula XI and contacting it with an amino compound of the formula H_2N-M-Q to form a compound of Formula XII



and


- 5 (c) removing the amino protecting group of the compound of Formula XII
and contacting the resulting free amine with an isocyanate having A to
form a compound of Formula I




10

25. A process for the preparation of compounds of Formula I, wherein A, M,
Q and R² are as defined above, comprising


- 15 (a) contacting a compound of Formula XVII with a bromoacetyl chloride
of the Formula XX to form a compound of Formula XXI



(b) contacting a compound of Formula XXI with an amine of Formula XXII to form a compound of Formula XXIII



5 (c) contacting a compound of Formula XXIII with an isocyanate having A to form a compound of Formula I




10 26. A process for the preparation of compounds of Formula I, wherein P¹ and P² are independent protecting groups and A, M, and Q are as defined above, comprising

15 (a) base catalyzed ring opening of a compound of Formula XXVIII to form a compound of Formula XXIX




- (b) contacting a compound of Formula XXIX with a reagent capable of forming a protecting group on the hydroxyl groups followed by contacting the resulting intermediate with a reagent capable of selective deprotection of the carboxylic acid hydroxyl group to form a compound with Formula XXX

5




10

- (c) activating the carboxylic acid of Formula XXX and contacting it with an amino compound of the formula XXXI to form a compound of Formula XXXII



15 and


(d) removing the amino protecting group of the compound of Formula XXXII and contacting the resulting free amine with an isocyanate having A to from a compound of Formula I



5


27. A process for the preparation of compounds of Formula I, wherein P¹ and P² are independent protecting groups and A, M, and Q are as defined above, comprising

10 (a) contacting a compound of Formula XXXIII with a reagent capable of selectively forming a protecting group on the alcohol hydroxyl group to form a compound with Formula XXXIV




15


(b) activating the carboxylic acid of Formula XXXIV and contacting it with an amino compound of the formula XXXV to form a compound of Formula XXXVI



(c) removing the amino protecting group of the compound of Formula XXXVI and contacting the resulting free amine with an isocyanate having A to from a compound of Formula XXXVII




(d) removing the alcohol hydroxy protecting group of the compound of Formula XXXVII to from a compound of Formula I




28. A process for the preparation of compounds of Formula I, wherein P¹ and P² are independently protecting groups and A, M, and Q are as defined above,
15 comprising


(a) contacting a compound of Formula XXXVIII with acid to form a compound of Formula XXXIX



5 (b) contacting a compound of Formula XXXIX with a reagent capable of forming a protecting group on the amino moiety to form a compound of Formula XL




10 (c) contacting a compound of Formula XL with a reagent capable of forming a protecting group on the heterocycle nitrogen to form a compound of Formula XLI




(d) contacting a compound of Formula XLI with a reagent capable of removing the protecting group of the carboxylic acid to form a compound of Formula XLII

5




(e) activating the carboxylic acid of Formula XLII and contacting it with an amino compound of the formula XLIII to form a compound of Formula XLIV

10



(f) removing the amino protecting group of the compound of Formula XLIV and contacting the resulting free amine with an isocyanate having A to from a compound of Formula I



29. A method of treating or preventing thrombotic disorders in a mammal comprising administering to said mammal a therapeutically effective amount of a compound according to claims 1 or 22.
- 10
30. The method of Claim 29, wherein said disorder is venous thrombosis.
31. The method of Claim 29, wherein said disorder is arterial thrombosis.
- 15 32. The method of Claim 29, wherein said disorder is pulmonary embolism.
33. The method of Claim 29, wherein said disorder is myocardial infarction.
34. The method of Claim 29, wherein said disorder is cerebral infarction.
- 20
35. The method of Claim 29, wherein said disorder is restenosis.
36. The method of Claim 29, wherein said disorder is cancer.
- 25 37. The method of Claim 29, wherein said disorder is angina.

38. The method of Claim 29, wherein said disorder is diabetes.
39. The method of Claim 29, wherein said disorder is atrial fibrillation.
- 5 40. The method of Claim 29, wherein said disorder is heart failure.
41. A method of inhibiting Factor Xa in a mammal comprising administering to said mammal a compound according to claims 1 or 22.
- 10 42. A pharmaceutical formulation comprising a compound of claim 1 or 22 admixed with a carrier, diluent, or excipient.